Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: COLL

Collegium Pharmaceutical, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic
$27.47
Market Cap$870M
Volume551.9K
EPS (TTM)$1.24

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is a $870M drug manufacturers - specialty & generic company trading at $27.47 — 22.1× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-10-11 00:47 UTC.

What Collegium Pharmaceutical, Inc. does

The company is a biopharmaceutical firm that develops, licenses, and acquires medications for treating ADHD and moderate to severe pain. Its product portfolio includes Jornay PM, an evening-dosed ADHD stimulant acquired through the purchase of Ironshore, along with pain-management medications Belbuca, Xtampza ER, the Nucynta Products, and Symproic, all commercialized in the United States. Jornay PM is the only FDA-approved stimulant medication dosed in the evening for ADHD in people six years and older, while Belbuca is a buccal film containing buprenorphine for severe persistent pain.

Summarized from Collegium Pharmaceutical, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Quote
Price$27.47
Market cap$870M
Volume551.9K shares
Valuation
P/E (TTM)22.15×
EV/EBITDA3.50×
EPS (TTM)$1.24
Price/book2.88×
Return on equity20.84%

Revenue, margins & earnings

FY2021 Revenue: $277M — margin split not shown (non-operating gains)$277MFY2021FY2022: net loss $25M on revenue $464M$464MFY2022FY2023 Net income: $48MFY2023 Taxes & interest: $119MFY2023 Operating expenses: $159MFY2023 Cost of revenue: $241M$567MFY2023FY2024 Net income: $69MFY2024 Taxes & interest: $101MFY2024 Operating expenses: $207MFY2024 Cost of revenue: $254M$631MFY2024FY2025 Net income: $63MFY2025 Taxes & interest: $117MFY2025 Operating expenses: $284MFY2025 Cost of revenue: $317M$781MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-06-10
Most recent filed transactions — June 2026:
  • 2026-06-10DirectorOption exercise8,700$143.5K
  • 2026-06-10DirectorOption exercise-8,700—
  • 2026-05-20DirectorSale-20$681
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Collegium Pharmaceutical, Inc. do?

The company is a biopharmaceutical firm that develops, licenses, and acquires medications for treating ADHD and moderate to severe pain.

What is COLL's valuation?

COLL trades at $27.47, 22.15× trailing earnings, 3.50× EV/EBITDA, as of 2026-10-11.

When did COLL last file with the SEC?

Collegium Pharmaceutical, Inc.'s most recent SEC filing on record is a 8-K filed 2026-08-13. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-10-11 00:47 UTC. This page is also available as JSON at /api/data?ticker=COLL and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for COLL and 5,000+ tickers.

Create a free account — keep COLL
For your agent
GET /api/data?ticker=COLL

This page as JSON via rel="alternate" · REST API docs · MCP server (62 tools) · llms.txt